XNAS
PODD
Market cap21bUSD
Jun 10, Last price
298.73USD
1D
-2.27%
1Q
20.27%
Jan 2017
692.81%
IPO
1,833.53%
Name
Insulet Corp
Chart & Performance
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 2,071,600 22.07% | 1,697,100 30.02% | 1,305,300 18.79% | |||||||
Cost of revenue | 845,500 | 742,200 | 679,900 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 1,226,100 | 954,900 | 625,400 | |||||||
NOPBT Margin | 59.19% | 56.27% | 47.91% | |||||||
Operating Taxes | (118,100) | 8,300 | 5,200 | |||||||
Tax Rate | 0.87% | 0.83% | ||||||||
NOPAT | 1,344,200 | 946,600 | 620,200 | |||||||
Net income | 418,300 102.76% | 206,300 4,384.78% | 4,600 -72.62% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 11,900 | 10,600 | (500) | |||||||
BB yield | -0.06% | -0.07% | 0.00% | |||||||
Debt | ||||||||||
Debt current | 83,800 | 49,400 | 27,500 | |||||||
Long-term debt | 1,395,900 | 1,401,700 | ||||||||
Deferred revenue | 1,600 | |||||||||
Other long-term liabilities | 1,347,700 | 37,900 | 35,700 | |||||||
Net debt | (869,600) | 714,500 | 739,500 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 430,300 | 145,700 | 119,000 | |||||||
CAPEX | (124,900) | (75,600) | (157,300) | |||||||
Cash from investing activities | (146,200) | (119,400) | (191,100) | |||||||
Cash from financing activities | (28,100) | (13,600) | (40,300) | |||||||
FCF | 1,297,500 | 678,900 | 589,200 | |||||||
Balance | ||||||||||
Cash | 953,400 | 704,200 | 674,700 | |||||||
Long term investments | 26,600 | 15,000 | ||||||||
Excess cash | 849,820 | 645,945 | 624,435 | |||||||
Stockholders' equity | 27,200 | (369,900) | (564,200) | |||||||
Invested Capital | 2,615,900 | 2,556,300 | 2,479,700 | |||||||
ROIC | 51.98% | 37.59% | 24.92% | |||||||
ROCE | 46.39% | 43.67% | 32.68% | |||||||
EV | ||||||||||
Common stock shares outstanding | 73,890 | 73,633 | 69,910 | |||||||
Price | 261.07 20.32% | 216.98 -26.30% | 294.39 10.64% | |||||||
Market cap | 19,290,462 20.74% | 15,976,888 -22.37% | 20,580,805 12.79% | |||||||
EV | 18,420,862 | 16,691,388 | 21,320,305 | |||||||
EBITDA | 1,306,900 | 1,027,700 | 688,600 | |||||||
EV/EBITDA | 14.10 | 16.24 | 30.96 | |||||||
Interest | 42,700 | 36,200 | 26,700 | |||||||
Interest/NOPBT | 3.48% | 3.79% | 4.27% |